{'52WeekChange': 1.9253733,
 'SandP52WeekChange': 0.0644362,
 'address1': '245 First Street',
 'address2': 'Suite 1400',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 11.75,
 'askSize': 1400,
 'averageDailyVolume10Day': 801737,
 'averageVolume': 1782241,
 'averageVolume10days': 801737,
 'beta': 1.503641,
 'beta3Year': None,
 'bid': 11.61,
 'bidSize': 1400,
 'bookValue': 3.043,
 'category': None,
 'circulatingSupply': None,
 'city': 'Cambridge',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 12.045,
 'dayLow': 11.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -9.734,
 'enterpriseToRevenue': 4.344,
 'enterpriseValue': 1523928576,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 871 2099',
 'fiftyDayAverage': 12.267285,
 'fiftyTwoWeekHigh': 13.71,
 'fiftyTwoWeekLow': 2.99,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 104320877,
 'forwardEps': -0.7,
 'forwardPE': -16.800001,
 'fromCurrency': None,
 'fullTimeEmployees': 358,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.03663,
 'heldPercentInstitutions': 0.63955003,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/akebia.com',
 'longBusinessSummary': 'Akebia Therapeutics, Inc., a biopharmaceutical '
                        'company, focuses on the development and '
                        'commercialization of renal therapeutics for patients '
                        "with kidney diseases. The company's lead product "
                        'candidate includes Auryxia, a ferric citrate to '
                        'control the serum phosphorus levels in adult patients '
                        'with chronic kidney disease (CKD), on dialysis '
                        '(DD)-CKD, or the hyperphosphatemia indication (HIF); '
                        'and vadadustat, an oral therapy, which is in Phase '
                        'III development for the treatment of anemia due to '
                        'CKD in DD and non-dialysis patients. It has '
                        'collaboration agreements with Otsuka Pharmaceutical '
                        'Co. Ltd. for the development and commercialization of '
                        'vadadustat in the United States, European Union, '
                        'Russia, China, Australia, Canada, the Middle East, '
                        'and other countries; and Mitsubishi Tanabe Pharma '
                        'Corporation for the development and commercialization '
                        'of vadadustat in Japan and other Asian countries, as '
                        'well as research and license agreement with Janssen '
                        'Pharmaceutica NV for the development and '
                        'commercialization of HIF-prolyl hydroxylases-targeted '
                        'compounds worldwide. The company was founded in 2007 '
                        'and is headquartered in Cambridge, Massachusetts.',
 'longName': 'Akebia Therapeutics, Inc.',
 'market': 'us_market',
 'marketCap': 1680692224,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_36644983',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -267984992,
 'nextFiscalYearEnd': 1640908800,
 'open': 11.8035,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '617 871 2098',
 'previousClose': 11.98,
 'priceHint': 2,
 'priceToBook': 3.8646073,
 'priceToSalesTrailing12Months': 4.790849,
 'profitMargins': -0.7639,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 12.045,
 'regularMarketDayLow': 11.31,
 'regularMarketOpen': 11.8035,
 'regularMarketPreviousClose': 11.98,
 'regularMarketPrice': 11.8035,
 'regularMarketVolume': 723710,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 142916000,
 'sharesPercentSharesOut': 0.0675,
 'sharesShort': 9641252,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 5039409,
 'shortName': 'Akebia Therapeutics, Inc.',
 'shortPercentOfFloat': 0.0777,
 'shortRatio': 5.57,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'AKBA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.211,
 'twoHundredDayAverage': 9.54241,
 'volume': 723710,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.akebia.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02142'}